期刊文献+

持续小剂量5-氟尿嘧啶静滴在乳腺癌新辅助化疗中的应用 被引量:5

下载PDF
导出
摘要 目的:观察持续小剂量5-氟尿嘧啶(5-FU)静脉滴注联合应用环磷酰胺(CTX)及蒽环类药物行乳腺癌新辅助化疗的近期疗效及毒性。方法:118例乳腺癌患者分为A、B两组,以5-FU200mg/(m2·d)持续静脉滴注,联合应用CTX500mg/(m2·d)及吡柔比星40mg/(m2·d),第1天及第14天行新辅助化疗,A组58例化疗14d,B组60例化疗21d。观察毒副反应及测量肿瘤大小变化,评估两组病例的近期疗效并进行对比分析。结果:A、B两组新辅助化疗的总有效率分别为77.6%和90.0%,差异有显著性(P<0.05)。两组的Ⅲ度毒性反应主要为骨髓抑制和消化道症状,发生率差异无显著性。结论:持续小剂量5-FU静脉滴注联合应用CTX及蒽环类药物行乳腺癌短程新辅助化疗,近期疗效满意、毒性反应小。化疗21d较14d疗效更好。
出处 《实用医学杂志》 CAS 2006年第24期2900-2901,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1李荔霞,张为民.肿瘤的新辅助化疗[J].实用医学杂志,2005,21(5):548-550. 被引量:3
  • 2KIM R, OSAKI A, TOGE T. Current and future roles of neoadjuvant chemotherapy in operable breast cancer [J], Clin Breast Cancer,2005,6(3): 223 - 232.
  • 3CANCE W G,CAREY L A,CALVO B F,et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival [J]. Ann Surg,2002,236(3):295 - 302.
  • 4范扬航,刘敦序.可手术乳腺癌术前化疗的疗效分析[J].实用医学杂志,2000,16(9):734-735. 被引量:1
  • 5李金锋,欧阳涛,王天峰,林本耀.原发性乳腺癌新辅助化疗的临床研究[J].中华肿瘤杂志,2004,26(8):493-495. 被引量:43
  • 6SMITH I E,AHERN R P,COOMBES G A,et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial [J]. Ann Oncol,2004,15(5): 751 - 758.
  • 7COLLEONI M, CURIGLIANO G, MINCHELLA I, et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase [J] .Ann Oncol,2003,14(10): 1477 - 1483.
  • 8SMITH I E, WALSH G, JONES A, et al. High complete remission rates with primary necadjuvant infusional chemotherapy for large early breast cancer [J]. Clin Oncol, 1995,13 (2): 424 - 429.

二级参考文献27

  • 1李树玲.Ⅰ、Ⅱ期乳腺癌全身性辅助治疗进展[J].实用肿瘤杂志,1995,10(3):131-132. 被引量:2
  • 2Rosen G. Management of malignant bone tumors in children and adolescents. Pediatr Clin North Am, 1976,23(2):183-213.
  • 3Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastase: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med, 1995,1(2):149-153.
  • 4Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18.J Clin Oncol, 1997, 15(7):2483-2493.
  • 5Hutcheon AW, Heys SD, Sarkar TK. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat, 2003, 79(Suppl 1):19-24.
  • 6Pierga JY, Mouret E, Laurence V, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response.Eur J Cancer, 2003, 39(8):1089-1096.
  • 7Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chem otherapy: predictive markers and relation with outcome.Br J Cancer, 2003, 88(3):406-412.
  • 8Tulbah AM, Ibrahim EM, Ezzat AA, et al. HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. Med Oncol, 2002, 19(1):15-23.
  • 9Lee SH, Chung MA, Quddus MR, et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg, 2003, 186(4):348-350.
  • 10Berend KR, Pietrobon R, Moore JO, et al. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol, 2001, 78(3):162-170.

共引文献44

同被引文献37

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部